Weikang Bio-Technology reiterates fiscal 2010 revenue guidance, targets growth of 30% to 50% for fiscal 2011

Weikang Bio-Technology Group Co., Inc. (OTC Bulletin Board: WKBT) ("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritional products in the People's Republic of China, today announced that the Company is reiterating its fiscal 2010 revenue guidance of $55 million, net profit of $21 million and earning per share of $0.75. The company also expects stockholders' equity to be $48 million or $1.71 per share. For fiscal year 2011, Weikang Bio-Technology is targeting revenue growth to be in the range of 30% to 50% over 2010 revenue.

Weikang Bio-Technology plans to launch two new therapeutics in the fourth quarter of 2010 and an additional three new therapeutics in the first quarter of 2011.  Combined, the new therapeutics are expected to add approximately $8.8 million in revenue and up to approximately $3.3 million in net income in 2011.  In addition, the recent launch of its new Rongrun Good Health Package has the potential to add approximately $8.5 million in revenue and $3.1 million in net income in 2011. In total, the new therapeutics and Good Health Package are expected to add up to $17.3 million in revenue and $6.4 million in net income for 2011.

"We are extremely excited about our growth prospects for 2011 and beyond.  We believe that the market for our high-quality therapeutics will continue to expand as China is expected to become the second largest pharmaceutical market by 2020," commented Mr. Yin Wang, Chairman and CEO of Weikang Bio-Technology Group. "Moreover, our research team is focused on developing new therapeutics that address a large number of health problems and have a broad consumer appeal."